MINAPHARM Pharmaceuticals Statistics
Total Valuation
MINAPHARM Pharmaceuticals has a market cap or net worth of EGP 2.08 billion. The enterprise value is 4.50 billion.
Market Cap | 2.08B |
Enterprise Value | 4.50B |
Important Dates
The last earnings date was Thursday, November 28, 2024.
Earnings Date | Nov 28, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
MINAPHARM Pharmaceuticals has 11.06 million shares outstanding.
Current Share Class | n/a |
Shares Outstanding | 11.06M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 1.66% |
Owned by Institutions (%) | n/a |
Float | 1.10M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.53 |
PB Ratio | 0.52 |
P/TBV Ratio | 0.62 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.63, with an EV/FCF ratio of -6.54.
EV / Earnings | -16.46 |
EV / Sales | 1.15 |
EV / EBITDA | 11.63 |
EV / EBIT | 30.15 |
EV / FCF | -6.54 |
Financial Position
The company has a current ratio of 1.14, with a Debt / Equity ratio of 1.36.
Current Ratio | 1.14 |
Quick Ratio | 0.76 |
Debt / Equity | 1.36 |
Debt / EBITDA | 14.39 |
Debt / FCF | -8.09 |
Interest Coverage | 0.36 |
Financial Efficiency
Return on equity (ROE) is -5.71% and return on invested capital (ROIC) is 1.14%.
Return on Equity (ROE) | -5.71% |
Return on Assets (ROA) | 0.97% |
Return on Capital (ROIC) | 1.14% |
Revenue Per Employee | 8.70M |
Profits Per Employee | -607,082 |
Employee Count | 450 |
Asset Turnover | 0.41 |
Inventory Turnover | 2.43 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.30% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -20.30% |
50-Day Moving Average | 166.24 |
200-Day Moving Average | 198.67 |
Relative Strength Index (RSI) | 66.05 |
Average Volume (20 Days) | 4,235 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MINAPHARM Pharmaceuticals had revenue of EGP 3.92 billion and -273.19 million in losses. Loss per share was -24.69.
Revenue | 3.92B |
Gross Profit | 1.01B |
Operating Income | 149.12M |
Pretax Income | -260.21M |
Net Income | -273.19M |
EBITDA | 343.18M |
EBIT | 149.12M |
Loss Per Share | -24.69 |
Balance Sheet
The company has 3.26 billion in cash and 5.56 billion in debt, giving a net cash position of -2.30 billion or -207.53 per share.
Cash & Cash Equivalents | 3.26B |
Total Debt | 5.56B |
Net Cash | -2.30B |
Net Cash Per Share | -207.53 |
Equity (Book Value) | 4.08B |
Book Value Per Share | 358.70 |
Working Capital | 658.27M |
Cash Flow
In the last 12 months, operating cash flow was 234.83 million and capital expenditures -921.86 million, giving a free cash flow of -687.03 million.
Operating Cash Flow | 234.83M |
Capital Expenditures | -921.86M |
Free Cash Flow | -687.03M |
FCF Per Share | -62.10 |
Margins
Gross margin is 25.70%, with operating and profit margins of 3.81% and -6.67%.
Gross Margin | 25.70% |
Operating Margin | 3.81% |
Pretax Margin | -6.64% |
Profit Margin | -6.67% |
EBITDA Margin | 8.76% |
EBIT Margin | 3.81% |
FCF Margin | -17.54% |
Dividends & Yields
This stock pays an annual dividend of 1.65, which amounts to a dividend yield of 0.88%.
Dividend Per Share | 1.65 |
Dividend Yield | 0.88% |
Dividend Growth (YoY) | -41.07% |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | 0.88% |
Earnings Yield | -13.11% |
FCF Yield | -32.98% |
Stock Splits
The last stock split was on March 19, 2009. It was a forward split with a ratio of 10.
Last Split Date | Mar 19, 2009 |
Split Type | Forward |
Split Ratio | 10 |
Scores
MINAPHARM Pharmaceuticals has an Altman Z-Score of 0.91. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 0.91 |
Piotroski F-Score | n/a |